376 related articles for article (PubMed ID: 19625999)
1. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.
Filipski KK; Mathijssen RH; Mikkelsen TS; Schinkel AH; Sparreboom A
Clin Pharmacol Ther; 2009 Oct; 86(4):396-402. PubMed ID: 19625999
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-induced renal injury is independently mediated by OCT2 and p53.
Sprowl JA; Lancaster CS; Pabla N; Hermann E; Kosloske AM; Gibson AA; Li L; Zeeh D; Schlatter E; Janke LJ; Ciarimboli G; Sparreboom A
Clin Cancer Res; 2014 Aug; 20(15):4026-35. PubMed ID: 24916697
[TBL] [Abstract][Full Text] [Related]
3. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.
Ciarimboli G; Deuster D; Knief A; Sperling M; Holtkamp M; Edemir B; Pavenstädt H; Lanvers-Kaminsky C; am Zehnhoff-Dinnesen A; Schinkel AH; Koepsell H; Jürgens H; Schlatter E
Am J Pathol; 2010 Mar; 176(3):1169-80. PubMed ID: 20110413
[TBL] [Abstract][Full Text] [Related]
4. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.
Franke RM; Kosloske AM; Lancaster CS; Filipski KK; Hu C; Zolk O; Mathijssen RH; Sparreboom A
Clin Cancer Res; 2010 Aug; 16(16):4198-206. PubMed ID: 20601443
[TBL] [Abstract][Full Text] [Related]
5. Interaction of Cisplatin with the human organic cation transporter 2.
Filipski KK; Loos WJ; Verweij J; Sparreboom A
Clin Cancer Res; 2008 Jun; 14(12):3875-80. PubMed ID: 18559608
[TBL] [Abstract][Full Text] [Related]
6. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations.
Jonker JW; Wagenaar E; Van Eijl S; Schinkel AH
Mol Cell Biol; 2003 Nov; 23(21):7902-8. PubMed ID: 14560032
[TBL] [Abstract][Full Text] [Related]
7. Wedelolactone protects against cisplatin-induced nephrotoxicity in mice via inhibition of organic cation transporter 2.
Wang G; Bi Y; Xiong H; Bo T; Han L; Zhou L; Zhang C; Zhang Y
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S447-S459. PubMed ID: 34592875
[TBL] [Abstract][Full Text] [Related]
8. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.
Iwata K; Aizawa K; Kamitsu S; Jingami S; Fukunaga E; Yoshida M; Yoshimura M; Hamada A; Saito H
Clin Exp Nephrol; 2012 Dec; 16(6):843-51. PubMed ID: 22569819
[TBL] [Abstract][Full Text] [Related]
9. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients.
Ciarimboli G; Lancaster CS; Schlatter E; Franke RM; Sprowl JA; Pavenstädt H; Massmann V; Guckel D; Mathijssen RH; Yang W; Pui CH; Relling MV; Herrmann E; Sparreboom A
Clin Cancer Res; 2012 Feb; 18(4):1101-8. PubMed ID: 22223530
[TBL] [Abstract][Full Text] [Related]
10. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).
Li Q; Guo D; Dong Z; Zhang W; Zhang L; Huang SM; Polli JE; Shu Y
Toxicol Appl Pharmacol; 2013 Nov; 273(1):100-9. PubMed ID: 24001450
[TBL] [Abstract][Full Text] [Related]
11. [Platinum agent-induced nephrotoxicity via organic cation transport system].
Yonezawa A
Yakugaku Zasshi; 2012; 132(11):1281-5. PubMed ID: 23123720
[TBL] [Abstract][Full Text] [Related]
12. Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity.
Guo D; Yang H; Li Q; Bae HJ; Obianom O; Zeng S; Su T; Polli JE; Shu Y
Pharm Res; 2018 Sep; 35(11):204. PubMed ID: 30191328
[TBL] [Abstract][Full Text] [Related]
13. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
Minematsu T; Iwai M; Umehara K; Usui T; Kamimura H
Drug Metab Dispos; 2010 Jan; 38(1):1-4. PubMed ID: 19833842
[TBL] [Abstract][Full Text] [Related]
14. The effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the nephrotoxicity in the mouse during repeated cisplatin (CDDP) treatments.
Yajima Y; Kawaguchi M; Yoshikawa M; Okubo M; Tsukagoshi E; Sato K; Katakura A
J Pharmacol Sci; 2017 Jun; 134(2):108-115. PubMed ID: 28648300
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin.
Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant C; Bowles DW; George B; Wen X; Aleksunes LM; Joy MS
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640195
[TBL] [Abstract][Full Text] [Related]
16. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.
Komazawa H; Yamaguchi H; Hidaka K; Ogura J; Kobayashi M; Iseki K
J Pharm Sci; 2013 Mar; 102(3):1086-94. PubMed ID: 23280877
[TBL] [Abstract][Full Text] [Related]
17. L-tetrahydropalmatine attenuates cisplatin-induced nephrotoxicity via selective inhibition of organic cation transporter 2 without impairing its antitumor efficacy.
Li C; Li L; Yi Y; Wang W; Yuan J; Tan F; Fang D; Zeng S; Zhou H; Jiang H
Biochem Pharmacol; 2020 Jul; 177():114021. PubMed ID: 32389634
[TBL] [Abstract][Full Text] [Related]
18. Renal circadian clock regulates the dosing-time dependency of cisplatin-induced nephrotoxicity in mice.
Oda M; Koyanagi S; Tsurudome Y; Kanemitsu T; Matsunaga N; Ohdo S
Mol Pharmacol; 2014 May; 85(5):715-22. PubMed ID: 24567546
[TBL] [Abstract][Full Text] [Related]
19. Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake.
Choi MK; Song IS
Biopharm Drug Dispos; 2012 Apr; 33(3):170-8. PubMed ID: 22415520
[TBL] [Abstract][Full Text] [Related]
20. PPAR-α Deletion Attenuates Cisplatin Nephrotoxicity by Modulating Renal Organic Transporters MATE-1 and OCT-2.
Freitas-Lima LC; Budu A; Arruda AC; Perilhão MS; Barrera-Chimal J; Araujo RC; Estrela GR
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33049997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
